Method for determining degree of modified potency of a medicament

专利摘要:
The invention comprises a method for determining degree of modified potency of a medicament. A medicine is a medicament comprising a therapeutic component and a homeopathic, i.e., activated-potentiated, component, wherein the activated-potentiated component has some physical, chemical or biological affect on the therapeutic component and/or the pharmacological efficacy thereof. The therapeutic component is biologically related to the starting substance of the homeopathic component. An analytical measurement of at least one characteristic parameter of the therapeutic form is made prior to its interaction with the activated-potentiated form. The same analytical measurement(s) are made and after interaction between the therapeutic and activated-potentiated forms. This data is used to confirm the presence of any modified potency is caused by the presence of molecular form in the activated-potentiated form. Further, the claimed analytical measurement of at least one characteristic parameter of the therapeutic form prior to its interaction with the activated- potentiated form and again after such interaction serves to quantify the degree of modifying potency associated with the activated-potentiated form in relative dimensionless activity units (release activity).
公开号:ES2560902A2
申请号:ES201590110
申请日:2014-03-18
公开日:2016-02-23
发明作者:Oleg Iliich Epshtein
申请人:Oleg Iliich Epshtein；
IPC主号:

专利说明:

image 1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image12
image13
image14
image15
image16
image17
image18
image19
image20
image21
image22
image23
image24
image25

权利要求:
Claims (1)
[1]
image 1
image2

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR112016017986A2|2017-10-10|isolated antibodies, isolated nucleic acid, host cell, methods of producing an antibody, treating cancer, treating a disease and detecting human jagged1 in a biological sample, immunoconjugate, pharmaceutical formulation and antibody use

---

BR112016006188A2|2017-08-01|method of treatment with a drug protocol and a relational database system coupled to one or more electronic devices; system for the management of a drug treatment by administering a drug to a patient; and method of managing a drug treatment using an information system with a relational database.

---

FR3006585B1|2015-05-29|TREATMENT PROCESS AND COMPOSITION COMPRISING AN IONIC LIQUID BASED ON AN ALPHA OXOACIDE OR ALPHA HYDROXYACID DERIVATIVE

---

UA117675C2|2018-09-10|METHOD FOR DETERMINING THE DEGREE OF MODIFYING ACTIVITY OF A BIPATIC MEDICINAL PRODUCT

---

EA201691860A1|2017-03-31|PEPTIDE MEDICINE AS A DRY POWDER

---

CL2016000944A1|2016-11-11|New formulation of ganadotropins

---

BR112016028838A2|2017-10-24|antibodies, nucleic acid, host cell, antibody production method, immunoconjugate, pharmaceutical formulation, methods of detecting human lgr5 in a biological sample, detecting a cancer, identifying a cancer patient, selecting a patient with cancer for treatment with an immunoconjugate and treatment of a cancer patient

---

ES2560902A2|2016-02-23|Method for determining degree of modified potency of a medicament

---

ES2722774A1|2019-08-16|Composition useful in detecting clavulanic acid allergy |

---

CL2016001054A1|2016-12-02|Compounds for the treatment of diabetes and complications of diseases derived from it

---

EA201600387A1|2016-08-31|DISPERSE SYSTEM FOR DELIVERY OF MEDICINE SUBSTANCE

---

EA202090988A1|2020-07-28|METHODS FOR TREATMENT OF FELAN-MACDERMIDE SYNDROME WITH FARNESIL DIBENZODIAZEPINONES

---

ES2589169A1|2016-11-10|Use of pentoxifiline and a pharmaceutical composition to prepare a medicine to prevent premature aging in humans |

---

ES2482468B1|2015-05-12|Method of obtaining useful data for differential diagnosis of lung cancer

---

TH1701004077A|2019-10-07|Active substance for improving early insulin secretion capacity.

---

ES2598805A1|2017-01-30|Kit for the treatment of external parasitosis in hives |

---

UA115025U|2017-03-27|METHOD OF PREVENTION OF THE NEURODYSTROPHIC SYNDROME IN PATIENTS WITH FALSE DISTAL DISEASE

---

TH166384A|2017-08-24|Cyclic Di-Nucleotide as an Modifier of STING

---

TH1701001011A|2021-02-15|Therapeutic agents for the treatment of psoriasis in patients receiving Anti-TNF-Alpha and using the drug

---

TR201503631U|2015-06-22|Insulin pen needle.

---

TH164080A|2017-07-06|Medicine picture of the stick

---

TH180367A|2018-10-11|Antibody-IL-13 / IL- 17 Bspecific antibody and its use

---

UA103900U|2016-01-12|Method for assessing extent and patterns of changes in microcirculation in children with diabetes type 1 in setting of ent pathology

---

BR112015021248A2|2017-07-18|apparatus and method for patient affection assessment

---

TH1601003451A|2019-10-07|Antibodies and methods of use

同族专利:

---

公开号 | 公开日

---

CN105264383A|2016-01-20|

---

EA201500925A1|2016-04-29|

---

GB201518062D0|2015-11-25|

---

US20140287448A1|2014-09-25|

---

GB2531930A|2016-05-04|

---

RU2013111962A|2014-09-27|

---

EA032090B1|2019-04-30|

---

MX2015013377A|2016-01-08|

---

AU2014242599A1|2015-10-15|

---

UA117925C2|2018-10-25|

---

DE112014001508T5|2016-05-19|

---

ES2560902R1|2016-03-31|

---

US9945798B2|2018-04-17|

---

WO2014155206A3|2015-01-22|

---

EP2976648A2|2016-01-27|

---

WO2014155206A9|2014-11-27|

---

WO2014155206A2|2014-10-02|

---

CA2907478A1|2014-10-02|

---

JP2016512893A|2016-05-09|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

NZ284214A|1994-03-31|1997-07-27|Biomed Comm Inc|Extreme dilutions of growth factors, homeopathic compositions, radiotherapy.|

---

IL125743A|1996-02-12|2003-09-17|Epshtein Oleg Iliich|Medicinal preparation containing an active medical substance with homeopathic potentiation|

---

RU2112976C1|1997-04-07|1998-06-10|Акционерное общество закрытого типа "Международный концерн "ЭДАС"|Method for determination of quality of homeopathic medicinal preparations and device for its realization|

---

EP1045250A1|1999-04-12|2000-10-18|INSTRUMENTATION LABORATORY S.p.A.|A global test for evaluating the functionality of the thrombin/antithrombin system|

---

RU2161955C1|1999-07-16|2001-01-20|Эпштейн Олег Ильич|Method of varying physico-chemical and biological properties of substance|

---

RU2181297C2|2000-06-20|2002-04-20|Эпштейн Олег Ильич|Method of treatment of pathological syndrome and medicinal agent|

---

RU2195648C2|2000-11-03|2002-12-27|Эпштейн Олег Ильич|Method of qualitative determination of homeopathic medicinal preparation or potentiated form of substance|

---

RU2192888C1|2001-02-15|2002-11-20|Эпштейн Олег Ильич|Medicinal agent and method of treatment of pathological syndrome|

---

RU2191601C1|2001-04-18|2002-10-27|Эпштейн Олег Ильич|Medicinal preparation and method for treating erectile dysfunctions|

---

RU2181890C1|2001-06-06|2002-04-27|Научно-исследовательский и учебно-методический центр биомедицинских технологий ВИЛАР|Method for selecting substances manifesting adaptogenic properties in vitro|

---

RU2201255C1|2001-12-26|2003-03-27|Эпштейн Олег Ильич|Medicinal agent and method of regulation of vascular tonus|

---

US20060153845A1|2002-08-02|2006-07-13|Epshtein Oleg I|Method for correcting immune respones and medical agent|

---

US7700096B2|2002-08-02|2010-04-20|Oleg Iliich Epshtein|Medicinal agent for treating erectile dysfunction|

---

EP1547611A4|2002-08-02|2006-01-25|Oleg Iliich Epshtein|Medicinal agent and method for curing prostate diseases|

---

UA76638C2|2002-08-02|2006-08-15|Oleh Illich Epshtein|Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon|

---

RU2253478C1|2003-10-01|2005-06-10|Эпштейн Олег Ильич|Agent for potentiation therapeutical effects: enhancing effect of drug|

---

RU2309732C1|2006-03-13|2007-11-10|Олег Ильич Эпштейн|Pressed solid oral formulation of medicinal preparation and method for preparing solid oral formulation of medicinal preparation|

---

CA2654408C|2006-06-06|2018-05-08|Oleg Iliich Epshtein|Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance|

---

RU2438707C2|2006-06-06|2012-01-10|Олег Ильич Эпштейн|Medication for per oral treatment of diabetes mellitus and other diseases accompanied by disturbance of tolerance to glucose, and method of obtaining hard drug form for per oral therapy of diabetes mellitus and other diseases, accompanied by disturbance of tolerance to glucose|

---

RU2332236C1|2007-02-02|2008-08-27|Олег Ильич Эпштейн|Medicine for bird influenza treatment|

---

AU2009285556B2|2008-08-29|2014-03-20|Cearna, Inc.|Homeopathic therapeutic method|

---

US20100233176A1|2008-10-06|2010-09-16|Cashman Neil R|Methods and systems for predicting misfolded protein epitopes|

---

US20130189707A1|2010-01-26|2013-07-25|Svetlana Alexandrovna Sergeeva|Method of determination of autoantibody level by means of enzyme immunoassay|

---

WO2011123388A1|2010-03-28|2011-10-06|Trustees Of The University Of Pennsylvania|Novel gene targets associated with amyotrophic lateral sclerosis and methods of use thereof|

---

US9556247B2|2010-05-25|2017-01-31|System Of Systems Analytics, Inc.|Stabilized amyloid-beta oligomers and uses thereof|

---

EA201300128A1|2010-07-15|2013-12-30|Олег Ильич ЭПШТЕЙН|COMBINED PHARMACEUTICAL COMPOSITION AND METHODS FOR THE TREATMENT OF DISEASES OR CONDITIONS ASSOCIATED WITH DISABILITY OF THE CARDIOVASCULAR SYSTEM|

---

MY158183A|2010-07-15|2016-09-15|Epshtein Oleg Lliich|Pharmaceutical compositions and methods of treatment|

---

DE112011102358T5|2010-07-15|2013-04-25|Oleg Iliich Epshtein|A method of increasing the effect of an activated-potentiated form of an antibody|

---

SG187035A1|2010-07-15|2013-02-28|Oleg Iliich Epshtein|Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract|

---

FR2962655A1|2010-07-15|2012-01-20|Oleg Iliich Epshtein|PHARMACEUTICAL ASSOCIATION COMPOSITION AND USES THEREOF IN METHODS OF TREATMENT OF GENITAL URINARY SYSTEM DISORDERS|

---

US8637034B2|2010-07-15|2014-01-28|Oleg I. Epshtein|Pharmaceutical compositions comprising activated-potentiated antibodies to interferon-gamma and S100 protein|

---

ITTO20110634A1|2010-07-21|2012-01-22|Oleg Iliich Epshtein|METHOD FOR TREATING ORGANIC DISEASES OF THE NERVOUS SYSTEM, THE PSYCHOORGANIC SYNDROME AND THE SYNTHALOPATHY|

---

EP2596018A2|2010-07-21|2013-05-29|Oleg Iliich Epshtein|Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia|

---

FR2962909A1|2010-07-21|2012-01-27|Oleg Iliich Epshtein|PHARMACEUTICAL ASSOCIATION COMPOSITION AND ITS USE IN METHODS FOR TREATING DISEASES OR DISORDERS ASSOCIATED WITH RESPIRATORY DISEASE OR DISEASE|

---

UA112755C2|2010-07-21|2016-10-25|Олєг Ільіч Епштейн|A method of treating attention deficit hyperactivity disorder|

---

EA029399B1|2010-07-21|2018-03-30|Олег Ильич ЭПШТЕЙН|Combination pharmaceutical composition for treating alzheimer's disease and method of treating alzheimer's disease|

---

EA029847B1|2010-07-21|2018-05-31|Олег Ильич ЭПШТЕЙН|Combination pharmaceutical composition and method of treating diabetes mellitus and associated metabolic disorders|

---

RU2535033C2|2010-08-06|2014-12-10|Олег Ильич Эпштейн|Therapeutic agent and method for prevention of hiv infection and treatment of hiv-caused or hiv-associated diseases, including aids|

---

CN103154030A|2010-08-06|2013-06-12|奥列格·伊里奇·爱泼斯坦|Combination pharmaceutical composition and methods of treating and preventing the infectious diseases|

---

RU2517084C2|2010-08-06|2014-05-27|Олег Ильич Эпштейн|Method and means for inhibiting production or enhancing protein p24 elimination|

---

RU2535034C2|2010-08-06|2014-12-10|Олег Ильич Эпштейн|Medication and method of preventing hiv infection, prevention and treatment of hiv-induced or hiv-associated diseases, including aids|

---

US20120263725A1|2010-08-06|2012-10-18|Epshtein Oleg Iiiich|Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV|

---

US20130171161A1|2010-12-23|2013-07-04|Oleg Iliich Epshtein|Method and composition for the treatment of diseases caused by or associated with hiv|

---

EP2666020A1|2011-01-18|2013-11-27|The United States of America, as represented by The Secretary, Department of Health and Human Services|Methods for amplification and detection of prions|

---

RU2013111961A|2013-03-18|2014-09-27|Олег Ильич Эпштейн|METHOD FOR DETERMINING THE EXPRESSION OF MODIFICATION ACTIVITY ASSOCIATED WITH A CARRIER|US20040190975A1|2003-02-07|2004-09-30|Closure Medical Corporation|Applicators, dispensers and methods for dispensing and applying adhesive material|

法律状态:
2017-05-22| FC2A| Grant refused|Effective date: 20170516 |

优先权:

---

申请号 | 申请日 | 专利标题

---

RU2013111962/15A|RU2013111962A|2013-03-18|2013-03-18|METHOD FOR DETERMINING THE EXPRESSION OF MODIFICATION ACTIVITY ASSOCIATED WITH A CARRIER|

---

RU2013111962|2013-03-18|

---